Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Want to cut your energy bills? Here’s how five experts are doing it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SOUTH SAN FRANCISCO, Calif., March 11, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2016 at 10:45 AM Eastern Daylight Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at https://cc.talkpoint.com/barc002/031516a_ae/?entity=133_M336FR1. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
